Tech Transfer Roundup: MD Anderson, NCI Lead Cancer Alliances
MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.
You may also be interested in...
Based on advice from the FDA, Cardiff is testing its PLK1 inhibitor onvansertib in first-line metastatic colorectal cancer; data from a discontinued second-line trial may support the hypothesis.
Looking to compete with Takeda’s Gattex in short bowel syndrome with intestinal failure, Ironwood succeeds in a Phase III trial, but investors may be concerned with misses on secondary endpoints.
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.